Key result
Cardiovascular biomarkers, including high-sensitivity troponins and natriuretic peptides, provide essential diagnostic and prognostic information for managing coronary, valvular, and cardiorenal diseases.
This expert review summarizes the clinical utility of established and emerging biomarkers for risk stratification, diagnosis, and prognosis across a wide spectrum of cardiovascular conditions.
May guide risk stratification across CV conditions; leaves open prospective validation of emerging biomarkers and guideline integration.
Cardiovascular diseases are the main causes of mortality and morbidity in Brazil. Their primary and secondary preventions are a priority for the health system and require multiple approaches for increased effectiveness. Biomarkers are tools used to identify with greater accuracy high-risk individuals, establish a faster diagnosis, guide treatment, and determine prognosis. This review aims to highlight the importance of biomarkers in clinical cardiology practice and raise relevant points regarding their application and perspectives for the next few years. This document was divided into two parts. This second part addresses the application of biomarkers in coronary heart disease, valvular diseases, cardio-oncology, pulmonary embolism, and cardiorenal syndrome.
No takes yet. Share an insight, caveat, or question.
A 2015 study conducted a review in Cardiovascular diseases (Coronary Heart Disease, Valve Disease, Cardio-oncology, Pulmonary Embolism, Cardiorenal Syndrome). Cardiovascular biomarkers was evaluated. Cardiovascular biomarkers, including high-sensitivity troponins and natriuretic peptides, provide essential diagnostic and prognostic information for managing coronary, valvular, and cardiorenal diseases.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: